- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:30 | BIODLINK-B (01875): DATE OF BOARD MEETING | - | HKEx | ||
| Fr | TOT BIOPHARM-B (01875): AMENDED AND RESTATED ARTICLES OF ASSOCIATION | - | HKEx | ||
| Fr | TOT BIOPHARM-B (01875): CHANGE OF COMPANY ENGLISH NAME, AMENDMENTS TO THE ARTICLES OF ASSOCIATION, CHANGE OF STOCK SHORT NAME, CHANGE OF COMPANY WEBSITE ... | - | HKEx | ||
| 30.06. | TOT BIOPHARM-B (01875): TERMS OF REFERENCE FOR THE NOMINATION COMMITTEE | - | HKEx | ||
| BIODLINK INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
| 20.06. | TOT BIOPHARM-B (01875): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 20 JUNE 2025 | - | HKEx | ||
| 06.06. | BioDlink Gains Argentina GMP Certification | 1 | Contract Pharma | ||
| 28.05. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 28.05. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 28.05. | TOT BIOPHARM-B (01875): FORM OF PROXY | - | HKEx | ||
| 28.05. | TOT BIOPHARM-B (01875): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 28.05. | TOT BIOPHARM-B (01875): PROPOSALS FOR GENERAL MANDATES TO ISSUE AND BUY BACK SHARES, RE-ELECTION OF RETIRING DIRECTORS, CHANGE OF COMPANY ENGLISH NAME ... | - | HKEx | ||
| 28.05. | TOT BIOPHARM-B (01875): PROPOSED CHANGE OF COMPANY ENGLISH NAME AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 2 | HKEx | ||
| 12.05. | TOT BIOPHARM-B (01875): CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2025 | - | HKEx | ||
| 28.04. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | 3 | HKEx | ||
| 28.04. | TOT BIOPHARM-B (01875): NOTIFICATION LETTER AND REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
| 28.04. | TOT BIOPHARM-B (01875): ANNUAL REPORT 2024 | 1 | HKEx | ||
| 21.03. | EQS Newswire: TOT BIOPHARM Turns a Profit for the First Time, Reports 2024 Net Income of RMB 34.8M | 360 | EQS Group (EN) | EQS Newswire / 21/03/2025 / 22:00 UTC+8
Guru Club, March 12 - TOT BIOPHARM - B (1875.HK) announced that for the full-year results ending December 31, 2024, the Company reported better-than-expected... ► Artikel lesen | |
| 21.03. | TOT BIOPHARM-B (01875): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 21.03. | TOT BIOPHARM-B (01875): CHANGE OF COMPOSITION OF BOARD COMMITTEE | - | HKEx | ||
| 12.03. | TOT BIOPHARM-B (01875): CHANGE OF DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES | 1 | HKEx |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 43,800 | -0,86 % | BERENBERG stuft QIAGEN NV auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 48 auf 50 Euro angehoben und die Einstufung auf "Buy" belassen. Analyst Harry Gillis "diagnostiziert" eine defensive... ► Artikel lesen | |
| EVOTEC | 7,046 | -4,78 % | Fast 200 % Kurspotenzial! Evotec, Plug Power, Empire Brand Building Aktie | Erstmals haben Analysten den Newcomer Empire Brand Building unter die Lupe genommen. Sie sehen bei dem Schweizer Betreiber von Social Media- und E-Commerce-Plattformen für Familien fast 200 % Kurspotenzial.... ► Artikel lesen | |
| BIONTECH | 94,25 | -2,23 % | KI-Aktien: SAP enttäuscht, BioNTech überrascht und NetraMark schlägt ChatGPT! | Schwach präsentiert sich gestern die Aktie von SAP. Dabei läuft es operativ bei der Softwareschmiede rund und beim Ausbau von KI- und Cloud-Geschäft kommt man voran. Bietet sich jetzt eine Chance zum... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,945 | +2,41 % | Recursion Pharmaceuticals: Recursion to Report Second Quarter 2025 Business Updates and Financial Results on August 5th | ||
| AVIDITY BIOSCIENCES | 36,650 | -0,62 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Completion of Enrollment for HARBOR, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory ... | -- Topline data readout from HARBOR study anticipated in Q2 2026 ---- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated... ► Artikel lesen | |
| PSYENCE BIOMEDICAL | 5,140 | -6,88 % | Pre-market Movers: VerifyMe, Psyence Biomedical, Pineapple Financial, Align Technology, Confluent | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green VerifyMe, Inc. (VRME) is up over 79% at $1.23.
Psyence... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,700 | +0,59 % | ADMA Biologics, Inc.: ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| COGENT BIOSCIENCES | 11,410 | -1,13 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced ... | -- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 26,350 | -1,16 % | Summit Therapeutics stock rating reiterated by Cantor Fitzgerald | ||
| MODERNA | 25,800 | -8,35 % | 3 Charts in 3x33 Sekunden - Heute mit Moderna, Silber und RWE | Willkommen zu '3 Charts in 33 Sekunden'! Jörg Scherer stellt uns drei Charts vor, die er aktuell ganz besonders unter die Lupe nimmt. Welche Ziele oder Signale jetzt wichtig sind, erfahren Sie im Video!... ► Artikel lesen | |
| DYNE THERAPEUTICS | 9,850 | -0,51 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Expected cash runway extended into Q3 2027, beyond multiple potential inflection points including Dyne's first planned commercial launch in early 2027 - - Registrational Expansion Cohort of DELIVER... ► Artikel lesen | |
| BEAM THERAPEUTICS | 19,720 | -2,09 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| BB BIOTECH | 35,600 | +2,89 % | BB Biotech: Comeback im Biotech-Wunderland - Q2 schlägt Nasdaq Biotech Index | Nach einem schwierigen Jahresstart stabilisierte sich das wirtschaftliche Umfeld im zweiten Quartal 2025 deutlich: Festgefahrene Leitzinsen, erste Zinssenkungssignale und sinkender Inflationsdruck stärkten... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 54,18 | -4,29 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| JANUX THERAPEUTICS | 24,030 | -0,83 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating |
BIODLINK INTERNATIONAL CO LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODLINK INTERNATIONAL CO LTD finden Sie auf Wallstreet Online.